A B S T R A C T Increased delivery of free fatty acids raises myocardial oxygen consumption (MV02) without influencing mechanical performance. The effects of norepinephrine on MV02 and on the size of ischemic injury after acute coronary occlusion were therefore studied before and during inhibition of lipolysis with P-pyridylcarbinol. In spite of similar mechanical responses to norepinephrine, MV02 increased by 57±11% before and significantly less, 31±6%, (P < 0.01) during inhibition of lipolysis. After coronary occlusion the ischemic injury associated with norepinephrine infusion, as evidenced by epicardial mapping of S-T segment elevation, was larger before (7.9±1
INTRODUCTION L-Norepinephrine has been widely used as a pressor agent in the treatment of cardiogenic hypotension (1) .
Although norepinephrine infusions of short duration are effective in raising peripheral vascular -resistance and increasing myocardial contractility, the results of prolonged infusions have been less satisfactory (2) (3) (4) .
There is reason to believe that agents altering the balance between myocardial oxygen supply and demand Received for publication 11 July 1972 and in revised form 7 January 1974. influence the extent and magnitude of ischemic injury after acute coronary occlusion (5) . Thus, isoproterenol has been shown to increase the extent and magnitude of the ischemic injury (6, 7) , probably due to raised myocardial oxygen demand out of proportion to oxygen supply. The hemodynamic effects of the naturally occurring catecholamine, norepinephrine, are not, however, comparable with those of isoproterenol in that norepinephrine is also a pressor agent. A rise in blood pressure alone has recently been shown to reduce the size of the ischemic injury after acute coronary occlusion in dogs (6) , and this might be caused by a larger rise in oxygen supply than demand in the ischemic area.
Although catecholamine-induced changes in myocardial oxygen consumption (MVO2) , or oxygen demand, have usually been attributed solely to increased mechanical activity of the heart (8-10), recent investigations have shown that a major fraction of the rise in MV02 effected by isoproterenol is related to excess release and consumption of FFA (11) (12) (13) . Since norepinephrine probably produces a similar effect, the first purpose of the present study was to determine the norepinephrine-induced rise in MVO2 and the fraction related to excess myocardial utilization of FFA.
Secondly, we proposed to investigate whether the raised oxygen demand of norepinephrine infusion would lead to increased myocardial ischemic injury after acute coronary occlusion as evidenced by epicardial S-T segment elevation (6) , and furthermore, whether norepinephrine-induced ischemic changes could be reduced 1 Abbreviations used in this paper: AP, mean aortic blood pressure; CO, cardiac output; dP/dt; maximal value of first derivative of LVP; HR, heart rate; LV'EDP, by inhibition of lipolysis, as shown for isoproterenol (7) . If this should be the case, part of a mechanism by which sustained norepinephrine infusion exerts myocardial damage might be explained, and could be pertinent in evaluating its value in the treatment of cardiogenic hypotension in man pretreated with antilipolytic agents.
METHODS
Experiments were carried out in 14 mongrel dogs of either sex (15-25 kg body wt), fasted for 12-15 h. The dogs were anesthetized with sodium pentobarbital, 25 mg/kg body wt, followed by maintenance doses. Sodium heparin, 3 mg/kg body wt, given i.v. was used as anticoagulant.
The dogs were divided into two experimental groups. Group I consisted of six close-chest dogs. Left ventricular pressure (LVP) was measured with a Statham P23Gb transducer (Statham Instruments, Inc., Oxnard, Calif.) connected to a radiopaque polyethylene tube introduced into the left ventricle from a carotid artery. The first derivative of LVP, dP/dt, was recorded continuously by means of a differentiator connected to the output from the pressure channel. Mean aortic blood pressure (AP) was recorded from a femoral artery with a Statham P23Gb transducer (Statham Instruments, Inc.). Cardiac output (CO) was determined by the thermal dilution technique and calculated according to Fegler (14) . Myocardial blood flow (MF) was measured polarographically by the hydrogen desaturation technique (15) (16) (17) . A platinum electrode was advanced to the coronary sinus and placed 3-4 cm from the atrial outlet. H2 was added to the tracheal tube, giving a concentration of about 2-5 vol/100 vol for 10 min, followed by ventricular infusion of 30-50 ml of saline saturated with dissolved H2 for 30-60 s. (17) . The response time for the electrode was 2-3 s at 90%o of full deflection (15) . The tissue/blood partition coefficient was assumed to be 1.00 (15, 16) . Arterial and coronary sinus blood samples were obtained simultaneously and analyzed for oxygen saturation by the method of Aukland (18) . Hemoglobin was measured spectrophotometrically as cyanmethemoglobin. The concentrations of FFA in arterial and coronary sinus blood were determined by the method of Dole (19) , as modified by Trout (22, 23) . S-T segment elevation has been shown to be reproducible after reocclusion of the vessel after a recovery period of 30 min. It is therefore possible to compare ischemic electrocardiographic changes during different interventions (6, 7) .
As an overall index of the severity of the ischemic injury in any given animal, the mean of S-T segment ele In two additional experiments, after a control occlusion, norepinephrine infusion was begun and maintained during the rest of the experiment. The coronary artery was permanently occluded. 15 min later 8-pyridylcarbinol was administered. Epicardial ECG and arterial blood samples were obtained as described above every 5 min.
RESULTS
Group I. Metabolic data before and after inhibition of lipolysis with P-pyridylcarbinol are given in Table I . Infusion of norepinephrine increased MV02 in all experiments, both before and during inhibition of lipolysis; however, the augmentation was larger (P <0.01) before than during inhibition (6.4±1.2 and 3.2±0.7 ml/ min 100 g, respectively). MF increased similarly with norepinephrine before and after inhibition of lipolysis (Fig. 1) . Administration of 8-pyridylcarbinol did not change the arterial hydrogen desaturation. The smaller rise in MV02, observed when norepinephrine was given with f-pyridylcarbinol, was therefore due to a reduction in myocardial oxygen extraction (P<0.01). Although plasma-FFA and myocardial uptake of FFA were markedly increased with norepinephrine alone, these increases were largely abolished by inhibition of lipolysis.
Hemodynamic data before and during i.v. infusion of norepinephrine, with and without inhibition of lipolysis, are presented in Table II . Inhibition of lipolysis did not influence the norepinephrine-induced changes in mechanical activity as evidence by AP, left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), dP/dt, heart rate (HR), and CO. When LVSP was raised by an average of 50 mm Hg in both sequences, LVEDP remained unchanged and dP/dt more than doubled, whereas HR and CO showed no consistent change.
Group II. i.v. infusion of norepinephrine, 2-3 l&g/ min, increased AP from an average of 104±5 to 156±4 mm Hg (P < 0.001), whereas HR remained unchanged or increased slightly (Table III) . Coronary occlusion or infusion of P-pyridylcarbinol did not effect further alterations in blood pressure or HR. Fig. 2 shows the results of one experiment. Under the influence of norepinephrine i.v., plasma-FFA, and average S-T segment elevation after 15 min of occlusion of a branch of the left anterior descending coronary artery were markedly higher than during control occlusion before drug administration. Pretreatment with fi-pyridylcarbinol, however, blocked the norepinephrineinduced rise in plasma-FFA and S-T segment elevation after repeated occlusion became even less .than during control occlusion alone, without drug administration. Approximately 3 h after discontinuing P-pyridylcarbinol administration, lipolysis had recovered, and with repeated occlusion during norepinephrine infusion, S-T segment elevation became nearly as high as when norepinephrine was infused before inhibition of lipolysis. No changes in S-T segments were observed in sites clearly outside the infarcted area.
A similar regression of S-T segment changes were obtained when P-pyridylcarbinol was administered after a permanent coronary occlusion and maintained norepinephrine infusion had caused extension of the ischemic area (Fig. 3) . Plasma-FFA and S-T segment elevation declined in a parallel fashion and reached levels below that obtained with control occlusion alone after about 30 min.
In experiments with six dogs, infusion of norepinephrine increased average S-T segment elevation from 4.4±0.7 to 7.9±1.1 mV (P < 0.005), and the number of sites with ischemic injury from 6.2±0.8 to 8.5±0.5 (P < 0.01) (Table III) . When P-pyridylcarbinol infusion was started before the norepinephrine administration, S-T segment elevation associated with subsequent coronary occlusion was markedly reduced, averaging 2.8±0.4 mV, compared to 7.9±1.1 mV during infusion of norepinephrine alone (P < 0.005). It should be noted that the S-T changes (2.8±0.4 mV) were even lower (P < 0.05) than during control occlusion before drug administration (4.4±0.7 mV). The number of sites with ischemic injury after coronary occlusion and norepinephrine infusion after pretreatment with fi-pyridyl- Myocardial equilibration was performed by adding hydrogen gas to the inspired air, followed by left ventricular infusion of H2-saturated saline. Arrows indicate the start of desaturation; the pens are separated by the distance between arrows. The chart speed was 10 mm/min during H2 breathing and 40 mm/min during H2 desaturation. (dog 6). (24, 25) . Increased endogenous lipolysis within the heart by catecholamines has also been suggested from in vitro experiments by Challoner and Steinberg (26, 27) . It is therefore conceivable that increased myocardial lipolysis may also contribute to the rise in MV02 by norepinephrine,,in addition to the effect of circulatory FFA. The higher MV02 effected by norepinephrine infusion ST, mean value of S-T segment elevation at 10-14 epicardial sites; AP, mean arterial blood pressure; HR, heart rate; FFAa, arterial concentrations of free fatty acids; P, probability values for comparison of paired data listed in the adjacent columns; NS, P > 0.05.
* Norepinephrine infusion, 2-3 pg/min; 1S-pyridylcarbinol, 5-10 mg/min.
alone was mainly due to larger myocardial oxygen extraction before inhibition of lipolysis whereas coronary blood flow was similarly increased. This is in accordance with previous studies in which FFA concentrations were raised by triglyceride/heparin infusion (24, 28) . The induced increase in MVO was obtained by an increase in coronary arterio-venous 02 difference. P-Pyridylcarbinol did not influence coronary flow in the present measurements although larger doses have been shown to reduce peripheral resistance in humans (29). This was probably not due to methodological errors in flow measurements since good correlation between coronary flow determination from H5 desaturation curves and by electromagnetic flowmetry has been shown over a wide range of flow values (15, 30) . Furthermore, previous experiments using electromagnetic flowmeters or collection of retrograde flow (28) are in accordance with the present findings. Whereas mechanical factors are by and large unchanged from prior control data, it should be noted that after inhibition of lipolysis, there is a substantial decrease in myocardial FFA uptake that is not translated into a decrease in MVO2. This probably indicates that under control conditions excess consumption of FFA does not take place, i.e., the substrate consumption equals the energy requirement. In a recent study it has been shown that the increase in MV02 for a given rise in arterial pressure is dependent on the arterial levels of FFA (13) . When MV02 was increased by elevating FFA concentrations before the pressure rise, the subsequent pressure-induced increased in MV02 was smaller than during pressure rise at control concentrations of FFA. Pressure loading increases the demand for substrate utilization. During increased uptake of FFA, available FFA are probably diverted into increased mechanical activity instead of being expended as heat only (31). Accordingly, it is only an increase in FFA over and above the substrate requirement set by the mechanical activity that will induce a change in oxygen consumption.
Although prolonged infusions of norepinephrine have been shown to produce myocardial necrosis and release of intracellular enzymes (3, 4) , no conclusion has been reached concerning the influence of norepinephrine on the development of myocardial injury after acute coronary occlusion. From the present experiments it seems clear that before inhibition of lipolysis, norepinephrine administration increased the ischemic injury after coronary artery occlusion, and that this was due to a larger rise in oxygen demand-through raised contractility, blood pressure, and uptake of FFA-than in oxygen supply. These findings are in agreement with the studies of Maroko et al. (6) and Kjekshus and Mjds (7), who showed that equivalent doses of isoproterenol (which do not produce ischemic injury in the normal myocardium) increased the extent and magnitude of S-T segment elevation and augmented the area of depression of creatine phosphokinase activity 24 h after coronary artery occlusion (6) .
Pretreatment with P-pyridylcarbinol lowered the norepinephrine-induced oxygen consumption in normal dog hearts, and a marked reduction was observed in the norepinephrine-induced ischemic injury when lipolysis was inhibited. As these effects occurred despite similar changes in the mechanical activity of the heart, and as P-pyridylcarbinol has not been found to increase blood flow in the normal or ischemic heart (7), it is suggested that the lesser ischemic injury may partly be due to blockade of FFA release. It was of interest that when P-pyridylcarbinol was given after permanent coronary occlusion and norepinephrine infusion had extended the ischemic injury, there was a close and related decline in plasma-FFA and S-T segment elevation. These findings are in accordance with a recent study showing that the increase in myocardial ischemic injury induced by isoproterenol was markedly reduced, but not abolished, by pretreatment with an antilipolytic agent (7). It should be noted, however, that during inhibition of lipolysis the norepinephrine-induced ischemic changes became significantly less than during simple control occlusion without the drug, indicating that in this setting norepinephrine resulted in a smaller ischemic area than in control occlusion alone.
Increased aortic pressure is generally believed to raise myocardial oxygen requirements. However, it has been demonstrated that the extent and magnitude of acute myocardial ischemic injury can be reduced by raising aortic blood pressure; conversely, a fall in blood pressure will increase the size of the injury (6) . The beneficial effect of raised aortic blood pressure is probably due to raised coronary perfusion pressure, and consequently increased collateral blood flow. The increased oxygen demand during the pressure rise thus encounters a larger rise in myocardial oxygen supply, resulting in reduced ischemic injury. This implies that in conjunction with P-pyridylcarbinol, norepinephrine raised myocardial oxygen supply, through increased collateral blood flow, more than the demand for oxygen was increased due to the rise in contractility and myocardial wall tension.
Although norepinephrine or isoproterenol induced essentially similar increases in MV02 as well as in myocardial ischemic injury after acute coronary occlusion, important hemodynamic differences exist (11) . AP was slightly reduced by i.v. infusion of isoproterenol, whereas norepinephrine in similar doses effected a 50 mm Hg rise. HR was found to increase more during isoproterenol than during norepinephrine infusion. A rise in HR has been shown to increase the size of a myocardial ischemic injury, probably due to increased oxygen demand (6) .
With intact lipolysis, isoproterenol or norepinephrine effect the same directional increase in myocardial ischemic injury. When lipolysis is inhibited, however, the differences in the extent and magnitude of the ischemic injury induced by norepinephrine and isoproterenol were different, and probably determined solely by their hemodynamic differences. The reduced size of the ischemic injury by norepinephrine in this setting may therefore be explained by the rise in blood pressure. On the other hand, the rise in ischemic injury effected by isoproterenol during inhibition of lipolysis may be due to the combination of a fall in blood pres-sure and increased HR and contractility. One explanation for the general reluctance to use sustained infusion of norepinephrine therapeutically is due to its untoward clinical effect which may be a result of unfavorable oxygen balance perhaps due to its lipolytic effect. When administered in conjunction with P-pyridylcarbinol, however, the effect of norepinephrine is to reduce oxygen demand and increase myocardial oxygen supply to an ischemic area. As a pure pressor and inotropic agent, norepinephrine may therefore be utilized successfully in cases of cardiogenic hypotension.
Interventions that alter infarct size may ultimately have clinical importance. Since treatment before coronary occlusion is hardly clinically applicable it is interesting that S-T segment elevation was decreased also when P-pyridylcarbinol was administered after a permanent occlusion and norepinephrine infusion had caused extension of the ischemic injury (Fig. 3) . 
